The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

Thu, 01st Feb 2024 07:42

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

The Bank of England will make its first interest rate decision of the year on Thursday at 1200 GMT. Alongside the decision, there will also be the BoE's latest monetary policy report, with economic projections, as well as a press conference with Governor Andrew Bailey half an hour later.

Like the US Federal Reserve and European Central Bank, the BoE is expected to keep interest rates unchanged.

New York ended lower on Wednesday, after Fed Chair Jerome Powell derailed market hopes for a March cut in interest rates.

Speaking after the Federal Open Market Committee voted to leave interest rates unchanged for the fourth meeting in a row, Powell said a rate cut in March, is not the "most likely case."

"I don't think it's likely that the committee will reach a level of confidence by the time of the March meeting, to identify that March is the time to do that," Powell told reporters at a press conference.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 0.3% at 7,606.80

----------

Hang Seng: up 0.4% at 15,553.55

Nikkei 225: closed down 0.8% at 36,011.46

S&P/ASX 200: closed down 1.2% at 7,588.20

----------

DJIA: closed down 317.01 points, 0.8%, at 38,150.30

S&P 500: closed down 79.32 points, 1.6% at 4,845.65

Nasdaq Composite: closed down 345.88 points, 2.2% to 15,164.01

----------

EUR: down at USD1.0801 (USD1.0846)

GBP: down at USD1.2670 (USD1.2715)

USD: up at JPY146.84 (JPY146.29)

Gold: down at USD2,043.40 per ounce (USD2,050.57)

(Brent): down at USD80.55 a barrel (USD81.03)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

09:30 EST Canada manufacturing PMI

10:00 CET eurozone manufacturing PMI

11:00 CET eurozone CPI

11:00 CET eurozone unemployment

09:50 CET France manufacturing PMI

09:55 CET Germany manufacturing PMI

09:30 GMT UK manufacturing PMI

12:00 GMT UK interest rate decision

07:30 EST US challenger job cuts

08:30 EST US initial jobless claims

08:30 EST US nonfarm productivity

09:45 EST US S&P Global manufacturing PMI

10:00 EST US ISM manufacturing PMI

10:00 EST US construction spending

10:30 EST US EIA natural gas storage

12:00 EST US 15-year fixed rate mortgage average

----------

EU leaders will grapple with Hungary's Prime Minister Viktor Orban at a crunch summit meeting Thursday to try to overcome his veto on EUR50 billion in financial aid for Ukraine. Orban – Russia's closest ally in the EU – sparked fury from his 26 counterparts in the bloc by thwarting a deal in December to keep the desperately needed funds flowing to Kyiv nearly two years into Moscow's invasion. The Hungarian populist has been accused of holding Ukraine's future hostage in a bid to blackmail Brussels into releasing billions of euros in frozen EU funds for Budapest. EU officials have been trying to thrash out a compromise with Hungary to get agreement on the four-year package for Ukraine as part of a broader overhaul of the bloc's budget.

----------

BROKER RATING CHANGES

----------

Barclays cuts Next to 'equal weight' (overweight)

----------

Berenberg raises Marshalls to 'buy' ('hold') - target 420 (320) pence

----------

Berenberg cuts Pets At Home to 'hold' (buy) - price target 390 (440) pence

----------

COMPANIES - FTSE 100

----------

Shell ups dividend despite profit nearly halving amid sharp drop in quarterly profit and revenue due to lower oil and gas prices. In the fourth quarter of 2023, the oil firms pretax profit fell to USD1.64 billion from USD16.44 billion a year earlier. Revenue dropped to USD78.73 billion from USD101.30 billion. Despite this, Shell upped its dividend to USD0.34 from USD0.29. This brings the full-year dividend to USD1.29 from USD1.04. Shell also said it has completed its USD3.5 billion share buyback and will now launch a new USD3.5 billion share buyback programme. "Shell delivered another quarter of strong performance, concluding a year in which we made good progress across the targets outlined at our Capital Markets Day. As we enter 2024 we are continuing to simplify our organisation with a focus on delivering more value with less emissions," said Chief Executive Wael Sawan. Shell expects a cash capital expenditure of USD22 billion to USD25 billion for 2024, compared to USD24.39 billion in 2023 and USD24.83 billion in 2022.

----------

BT said it is on track for its full-year financial outlook, after growth in revenue and Ebitda during its third quarter ended December 31. Third quarter adjusted revenue rose 3% annually to GBP5.34 billion from re-presented revenue of GBP5.21 billion. Adjusted Ebitda edged up 1% to GBP2.03 billion from re-represented GBP2.01 billion. "BT Group has delivered another quarter of revenue and EBITDA growth, while rapidly building and upgrading customers to our full-fibre broadband and 5G networks, and we continue to be on track to achieve our financial outlook for the year," said Chief Executive Allison Kirkby. "We are providing great digital connectivity and services, while laying the foundations for future growth that will benefit our customers, investors and the UK.

----------

GSK confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court. The litigation related to its heartburn medication Zantac, also known as ranitidine. The pharmaceutical company said the case was set to go to trial on February 20, and instead will now be dismissed. "The settlement reflects the company's desire to avoid the distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases," GSK said.

----------

COMPANIES - FTSE 250

----------

AG Barr said that in its financial year ended January 28, revenue jumped 26% to GBP400 million from GBP317.6 million in the 52 weeks ended January 29, 2023. Adjusted pretax profit is now expected to be about GBP49.5 million, up 14% on the prior year's result of GBP43.5 million and slightly ahead of previous market expectations. AG Barr also named Euan Sutherland as its new chief executive officer. For the role will be effective from May 1. Most recently, Sutherland was CEO of Saga. As announced in August last year, Roger White will step down from the board at the end of April 2024 and will remain available until the end of July to support a smooth leadership transition as planned. Chair Mark Allen said: "On behalf of the board, I am delighted that Euan is joining AG Barr. He has substantial experience across several consumer-facing businesses and will be a strong addition to the board. He is well placed to lead AG Barr through the next exciting phase of its development and to ensure the continued long term success of the business."

----------

OTHER COMPANIES

----------

Gresham House Energy Storage Fund said it continues to be impacted by a "weak revenue environment." It noted the slower than expected pace of commissioning of new projects to date, due to elongated grid connection times; battery energy storage systems being significantly under-utilised in National Grid ESO's Balancing Mechanism; and the excessive use of legacy gas-fired electricity generation by ESO to provide the BM with flexible generation which in turn causes oversupply in the wholesale electricity market. Chair John Leggate said: "The challenging environment continues to persist for the battery storage industry in Great Britain as it transitions to a trading-focused business model, having been focused on frequency response until Q1 2023. These conditions, and their effect on revenues, are not unique to GRID."

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.